Side Effects of Elmiron Caused Permanent Vision Damage, Lawsuit Claims

A recently filed lawsuit alleges that side effects of Elmiron caused a long-term user of the bladder drug to suffer permanent vision damage, indicating that the eye problems could have been avoided or less severe if the drug makers had properly disclosed the risk.

The complaint (PDF) was filed by Lynn Brewer in the U.S. District Court for the District of New Jersey on June 24, indicating Janssen Pharmaceuticals, its Johnson & Johnson parent company, and Teva Pharmaceuticals knew or should have known about the link between Elmiron and vision damage, yet withheld information from users and the medical community.

Elmiron (pentosan polysulfate sodium or PPS) is the only approved drug treatment for interstitial cystitis or “painful bladder syndrome”, and has been marketed as safe and effective since 1996. Although concerns existed for years among vision specialists about the risk of retina damage, Elmiron vision warnings were not added to the drug label in the U.S. until last month.

Learn More About

Elmiron Lawsuits

Side effects of Elmiron have been associated with vision loss and retina damage known as pigmentary maculopathy.

Learn More About this Lawsuit See If You Qualify Now >

The label update comes after a series of independent studies and case reports published in recent years have highlighted cases involving visual injury and pigmentary changes in the retina among long-term users of Elmiron. The drug has been linked to the development of a rare retinal disease known as pigmentary maculopthy, which can cause users to experience difficulty adjusting in dark light, problems reading, centralized dark spots and other complications.

Brewer indicates she began taking Elmiron in 2005, for the treatment of interstitial cystitis-related pain. However, that same year, shortly after beginning treatment, she was diagnosed with vision loss due to maculopathy and other vision injuries. Since information about the toxic side effects of Elmiron on the retina were not disclosed by the drug makers, she continued to use the medication until 2019, causing further damage.

In addition to Elmiron-associated maculopathy, Brewer indicates she suffered severe vision degradation, loss of nightvision, changes in eye color pigment and pigmentary maculopathy, the lawsuit states.

“Mrs. Brewer would not have used Elmiron had any or all of Defendants’ properly disclosed the risks associated with its use,” according to her lawsuit. “Mrs. Brewer’s injuries could have been avoided or would have been less severe had any or all of Defendants properly disclosed the risks associated with its use.”

The complaint comes as a growing number of Elmiron vision damage lawsuits are now being filed throughout the federal court system. Since most ophthalmologists were previously unaware that side effects of Elmiron may impact the eyes, many individuals indicate they were previously misdiagnosed with other retinal diseases, such as macular degeneration, pattern dystrophy and other problems.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Philips CPAP Lawsuit Filing Deadlines May Be Approaching in Some Claims
Philips CPAP Lawsuit Filing Deadlines May Be Approaching in Some Claims (Posted yesterday)

Lawyers are working to register and file Philips CPAP lawsuits, as the manufacturer may argue the June 14 anniversary of a massive recall triggered the start of the statute of limitations in certain states